Nicholas Piramal Says Contract Research Progressing, Avecia Unit Profitable
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Nicholas Piramal said its growing contract research business, forecast to be a separately listed unit by June, has four potential compounds in Phase I to Phase II trials while its Avecia Pharmaceuticals unit has turned profitable